Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hypercalcaemia of malignancy Age: Adult |
Dose: Intravenous infusion – 4 mg Frequency: single dose Note: Infusion over at least 15 minutes. |
|
Indication: Hypercalcaemia of malignancy Age: Adult Condition: Relapse or refractory to initial treatment |
Dose: Intravenous infusion – 4 mg Frequency: single dose Note: Infusion over at least 15 minutes; retreatment after at least 1 week from initial dose. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Form not specified – Safety and efficacy not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with CrCl greater than 60 mL/min Condition: Renal impairment with CrCl 50-60 mL/min Condition: Renal impairment with CrCl 40-49 mL/min Condition: Renal impairment with CrCl 30-39 mL/min Condition: Renal impairment with CrCl less than 30 mL/min |
Dose: 4 mg Dose: 3.5 mg Dose: 3.3 mg Dose: 3 mg Dose: Not recommended |
Administration
- For hospital use only
- Must be given by IV infusion
Side Effect
- Arthralgia
- fever
- flu-like symptoms
- myalgia
- headache
- pain in extremity
- nausea
- vomiting
- diarrhoea
- eye inflammation
- alopecia
- hyperhidrosis
- bone/joint/muscle pain
- osteonecrosis of the jaw
- femoral fracture
- hypersensitivity reactions (eg urticaria, angioedema)
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- hypotension
- Severe hypocalcaemia
- severe kidney problems
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Aminoglycosides, loop diuretics (Furosemide, Bumetanide, Ethacrynic acid, Torsemide)
|
Increased risk of hypocalcaemia
|
|
Nephrotoxic agents
|
Increased risk renal dysfunction
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypocalcemia
|
Risk of worsening calcium deficiency
|
|
Severe Renal Impairment
|
Risk of kidney damage
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 30° C prior to opening. Protect from moisture and light. Zoledronic Acid must be kept out of the reach and sight of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.